依达拉奉辅助治疗急性脑梗死的疗效和安全性分析  

Analysis of Clinical Efficacy and Safety of Edaravone in the Adjuvant Treatment of Acute Cerebral Infarction

作　　者：潘浩泉[1] 胡金伦[1] 温宇明[1] 孙毅[1] 

机构地区：[1]广东省佛山市第一人民医院急诊科,广东佛山528000

出　　处：《临床医学工程》2015年第2期186-187,共2页Clinical Medicine & Engineering

摘　　要：目的探讨依达拉奉辅助治疗急性脑梗死的有效性和安全性。方法将我院收治的48例急性脑梗死患者随机均分为观察组和对照组各24例。对照组给予醒脑静进行治疗,观察组在对照组治疗的基础上给予依达拉奉进行治疗。采用神经功能缺损评分(NIHSS)评价患者的神经功能,Barthel指数评价患者的日常生活活动能力(ADL)。观察比较两组的临床疗效,NIHSS、ADL评分和不良反应情况。结果观察组治疗总有效率为87.5%,显著高于对照组的62.5%,差异具有统计学意义(P<0.05);治疗后,观察组患者NIHSS、ADL评分均显著优于对照组,差异有统计学意义(P<0.05);两组患者均无严重不良反应出现,不良反应发生率比较无显著差异(P>0.05)。结论依达拉奉联合醒脑静治疗急性脑梗死效果显著,可有效改善患者神经功能缺损,无严重不良反应,值得临床推广应用。Objective To investigate the clinical efficacy and safety of edaravone in the adjuvant treatment of acute cerebral infarction. Methods 48 cases of acute cerebral infarction treated in our hospital were randomly divided into observation group（24 cases）and control group（24 cases）. The control group was treated with xingnaojing, while the observation group was given edaravone on the basis of the control group. The nerve function was evaluated by national institutes of health stroke scale（NIHSS）, activities of daily living（ADL）was evaluated by Barthel index. The clinical efficacy, NIHSS score, ADL score and adverse reactions of two groups were observed and compared. Results The total effective rate of observation group was 87.5%, significantly higher than 62.5% of control group, with statistical difference（P 0.05）; after treatment, the NIHSS and ADL scores of observation group were significantly better than those of control group,with statistical difference（P 0.05）; both of two groups had no serious adverse reactions, the difference was not statistical（P 0.05）.Conclusions Edaravone combined with xingnaojing has significant effect in the treatment of acute cerebral infarction. The treatment method can effectively improve patients＇ neurologic impairment without serious adverse reactions, which is worthy of clinical promotion.

关 键 词：依达拉奉 醒脑静 急性脑梗死 临床疗效 

分 类 号：R743.3[医药卫生—神经病学与精神病学]